Sotera Health Reports Record Q4 2023 Non-GAAP EPS of $0. 25, Beating Estimates by $0. 03.
March 3, 2023
Trending News 🌧️
Sotera Health ($NASDAQ:SHC) recently reported record Q4 2023 non-GAAP earnings per share (EPS) of $0.25, beating analyst estimates by $0.03. This marks an impressive performance for the healthcare company as they continue to expand their offerings and find new ways to capitalize on the growing healthcare industry. The company’s success can be attributed to several factors. For starters, they have been able to secure contracts with a number of leading healthcare organisations throughout the year, allowing them to expand their operations.
Additionally, the company has implemented a range of cost-cutting measures that have helped to drive down their operational expenses, leading to higher profitability. Moreover, Sotera Health has seen strong growth in their healthcare services business as well. This is due in part to the increasing demand for such services, as well as the development of innovative technologies that are changing the face of healthcare and making it more accessible. Thanks to these factors, the company has been able to grow its revenue and profits significantly over the course of the year. The company is expected to continue its impressive performance in the coming quarters and years, as it continues to capitalise on the growth opportunities in healthcare.
Price History
This announcement caused their stock to open at $17.5 and close at $16.7, representing a decrease of 2.8% from the previous closing price of $17.2. While the stock decreased slightly, this announcement is still seen as positive news for Sotera Health and it’s investors. The strong results demonstrate the potential of the company and suggest that Sotera Health could be a promising investment for the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sotera Health. More…
| Total Revenues | Net Income | Net Margin |
| 1k | -233.57 | 16.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sotera Health. More…
| Operations | Investing | Financing |
| 277.96 | -181.9 | 197.76 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sotera Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.12k | 2.77k | 2.15 |
Key Ratios Snapshot
Some of the financial key ratios for Sotera Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.8% | 9.5% | -16.2% |
| FCF Margin | ROE | ROA |
| 9.5% | -21.3% | -3.3% |
Analysis
At GoodWhale, we’ve taken a look at SOTERA HEALTH to provide you with the best analysis possible. After a thorough investigation of the company, we have determined that, according to our Risk Rating, SOTERA HEALTH is a medium risk investment in terms of financial and business aspects. When delving deeper into the company’s balance sheet and cashflow statement, we have detected two risk warnings. Become a registered user of GoodWhale to check these items out, and gain more information about SOTERA HEALTH’s wellbeing. More…
Peers
The company has a strong presence in the United States, Europe, and Asia. Pharmigene Inc, Inotiv Inc, and Centogene NV are all major competitors of Sotera Health Co.
– Pharmigene Inc ($TPEX:7595)
Pharmigene Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer and other diseases. The company’s lead product candidate is PG-301, a precision cancer medicine targeting the EZH2 protein. Pharmigene is also developing PG-201, a precision medicine targeting the KRAS protein, and PG-102, a precision medicine targeting the BRAF protein.
Pharmigene’s market cap is $658.49 million as of 2022. The company’s return on equity is -6.26%.
Pharmigene’s lead product candidate, PG-301, is a precision cancer medicine targeting the EZH2 protein. The company is also developing PG-201, a precision medicine targeting the KRAS protein, and PG-102, a precision medicine targeting the BRAF protein.
– Inotiv Inc ($NASDAQ:NOTV)
Inotiv Inc is a biotechnology company that focuses on the discovery and development of innovative therapies to treat patients with cancer and other serious diseases. The company’s market cap is $486.81M as of 2022, and its ROE is -6.96%. Inotiv’s products are designed to target the underlying cause of disease and improve patient outcomes. The company’s lead product candidates are in clinical trials for the treatment of solid tumors and blood cancers. Inotiv is headquartered in San Diego, California.
– Centogene NV ($NASDAQ:CNTG)
As of 2022, Centogene NV has a market cap of 28.16M. The company’s return on equity is -141.43%. Centogene NV is a biotechnology company that focuses on the diagnosis, treatment, and prevention of rare diseases. The company was founded in 2002 and is headquartered in Rostock, Germany.
Summary
Sotera Health reported strong results for Q4 2023 with Non-GAAP earnings per share (EPS) of $0.25, beating estimates by three cents. This positive performance was driven by year-over-year increases in revenue, gross margin, and operating income, as well as a lower tax rate. The company’s diversified portfolio of products and services, as well as its strategy of scaling operations and expanding global presence, are contributing to its success.
Investors should be encouraged by these financial results and the growth potential of the company in the coming years. Sotera Health is well positioned to capitalize on market trends and offer attractive returns over the long term.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
